Stockscreener 앱 받기
39.96
1.73%
0.6229
전일 마감가:
$39.34
열려 있는:
$39.39
하루 거래량:
54,156
Relative Volume:
0.17
시가총액:
$3.00B
수익:
$13.17M
순이익/손실:
$-199.06M
주가수익비율:
-16.05
EPS:
-2.49
순현금흐름:
$-156.53M
1주 성능:
-4.14%
1개월 성능:
-9.48%
6개월 성능:
+2.67%
1년 성능:
+33.27%
1일 변동 폭
$38.71
$40.20
1주일 범위
$37.34
$41.42
52주 변동 폭
$28.20
$50.99
Xenon Pharmaceuticals Inc Stock (XENE) Company Profile
명칭
Xenon Pharmaceuticals Inc
전화
(604) 484-3300
주소
200 - 3650 GILMORE WAY, BURNABY
XENE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| XENE | 39.98 | 3.00B | 13.17M | -199.06M | -156.53M | -2.49 |
| VRTX | 447.18 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 741.71 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 589.39 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.84 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 103.36 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Xenon Pharmaceuticals Inc Stock (XENE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-10-01 | 개시 | H.C. Wainwright | Buy |
| 2024-01-04 | 개시 | Citigroup | Buy |
| 2023-12-08 | 개시 | Robert W. Baird | Outperform |
| 2023-10-24 | 재개 | Cantor Fitzgerald | Overweight |
| 2023-04-25 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-12-14 | 개시 | Goldman | Buy |
| 2022-12-12 | 개시 | Cowen | Outperform |
| 2022-11-28 | 개시 | Wells Fargo | Overweight |
| 2022-10-19 | 개시 | Raymond James | Outperform |
| 2022-08-29 | 개시 | BofA Securities | Buy |
| 2022-07-21 | 개시 | JP Morgan | Overweight |
| 2021-10-28 | 개시 | RBC Capital Mkts | Outperform |
| 2020-10-02 | 개시 | SVB Leerink | Outperform |
| 2020-07-21 | 개시 | Needham | Buy |
| 2020-06-01 | 재개 | Jefferies | Buy |
| 2020-03-25 | 개시 | Wedbush | Outperform |
| 2020-01-08 | 개시 | William Blair | Outperform |
| 2019-09-20 | 개시 | Guggenheim | Buy |
| 2018-08-08 | 재확인 | Stifel | Buy |
| 2017-03-13 | 개시 | Jefferies | Buy |
| 2016-10-21 | 개시 | Stifel | Buy |
| 2016-09-26 | 개시 | Guggenheim | Buy |
| 2016-04-14 | 재확인 | Jefferies | Buy |
| 2015-10-30 | 재개 | Jefferies | Buy |
| 2014-12-02 | 개시 | Canaccord Genuity | Buy |
모두보기
Xenon Pharmaceuticals Inc 주식(XENE)의 최신 뉴스
First Turn Management LLC Sells 14,658 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - MarketBeat
Investors Eye Opportunities With Xenon Pharmaceuticals - Evrim Ağacı
Xenon Pharmaceuticals (NASDAQ:XENE) Shares Gap DownHere's What Happened - MarketBeat
Equities Analysts Issue Forecasts for XENE FY2024 Earnings - MarketBeat
FY2024 EPS Estimates for XENE Reduced by Cantor Fitzgerald - MarketBeat
How to Take Advantage of moves in (XENE) - Stock Traders Daily
Q1 Earnings Forecast for XENE Issued By HC Wainwright - MarketBeat
What is Wedbush's Estimate for XENE FY2024 Earnings? - MarketBeat
Leerink Partnrs Has Pessimistic View of XENE FY2024 Earnings - MarketBeat
Needham & Company LLC Reaffirms Buy Rating for Xenon Pharmaceuticals (NASDAQ:XENE) - Defense World
Stock Traders Purchase Large Volume of Xenon Pharmaceuticals Put Options (NASDAQ:XENE) - MarketBeat
GSA Capital Partners LLP Purchases 30,830 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - MarketBeat
Xenon Q3 Loss Narrower Than Expected, Pipeline Development in Focus - MSN
Xenon to Present at Upcoming Investor Conferences - The Manila Times
Xenon Pharmaceuticals (NASDAQ:XENE) Announces Quarterly Earnings Results - MarketBeat
Needham & Company LLC Reaffirms "Buy" Rating for Xenon Pharmaceuticals (NASDAQ:XENE) - MarketBeat
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q3 2024 Earnings Call Transcript - Insider Monkey
Xenon Pharmaceuticals: Q3 Earnings Snapshot - mySA
Xenon Pharmaceuticals Inc (XENE) Q3 2024 Earnings Call Highlight - GuruFocus.com
Xenon Pharmaceuticals Inc (XENE) Q3 2024 Earnings Call Highlights: Strategic Advancements and ... - Yahoo Finance
Xenon Pharmaceuticals Reports Q3 2024 Progress and Outlook - TipRanks
Xenon Reports Q3 2024 Financial Results and Business Update - The Manila Times
Xenon Pharmaceuticals Reports $803M Cash Position, Advances Epilepsy Drug Pipeline | XENE Stock News - StockTitan
Earnings To Watch: Xenon Pharmaceuticals Inc (XENE) Reports Q3 2 - GuruFocus.com
TimesSquare Capital Management LLC Purchases 23,800 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - MarketBeat
Fiera Capital Corp Sells 28,679 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - MarketBeat
Xenon Pharmaceuticals (XENE) Scheduled to Post Quarterly Earnings on Tuesday - MarketBeat
Xenon to Report Q3 2024 Financial Results on November 12, 2024 - StockTitan
Harbor Capital Advisors Inc. Buys 23,947 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - MarketBeat
Allspring Global Investments Holdings LLC Sells 21,269 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - Defense World
New Horizons in Tonic-clonic Seizure Market Exploring Future - openPR
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Bought by abrdn plc - MarketBeat
Repligen Co. (NASDAQ:RGEN) Position Boosted by Blue Trust Inc. - Defense World
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Average Rating of “Buy” by Brokerages - Defense World
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Sold by Creative Planning - Defense World
Creative Planning Buys 2,475 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - Defense World
Blue Trust Inc. Has $39,000 Stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Average Rating of "Buy" by Brokerages - MarketBeat
Xenon Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:XENE) - MarketBeat
Epilepsy Clinical Trials 2024: EMA, PDMA, FDA Approvals, - openPR
Xenon Pharmaceuticals (NASDAQ:XENE) Shares Pass Above 50-Day Moving AverageHere's What Happened - MarketBeat
Assenagon Asset Management S.A. Acquires 138,685 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - MarketBeat
When (XENE) Moves Investors should Listen - Stock Traders Daily
SG Americas Securities LLC Sells 18,463 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - MarketBeat
Leerink Partnrs Has Negative Outlook of XENE FY2026 Earnings - MarketBeat
Stock Traders Purchase Large Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE) - MarketBeat
How To Trade (XENE) - Stock Traders Daily
Intra-Cellular's Caplyta Sales Boost Revenues, Dependence a Woe - Zacks Investment Research
Millennium Management LLC Increases Holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - MarketBeat
Xenon Pharmaceuticals Inc (XENE)’s Day in Review: Closing at 39.42, Down by -3.90 - The Dwinnex
Raymond James sets steady target on Xenon Pharmaceuticals By Investing.com - Investing.com UK
Xenon Pharmaceuticals Inc (XENE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Xenon Pharmaceuticals Inc 주식 (XENE) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| GAROFALO ELIZABETH A. | Director |
Mar 08 '24 |
Sale |
45.69 |
2,092 |
95,583 |
0 |
| ROBIN SHERRINGTON | EVP, Strategy & Innovation |
Mar 07 '24 |
Option Exercise |
9.85 |
8,641 |
85,114 |
16,824 |
| ROBIN SHERRINGTON | EVP, Strategy & Innovation |
Mar 07 '24 |
Sale |
46.28 |
7,137 |
330,290 |
8,398 |
| GANNON STEVEN | Director |
Mar 07 '24 |
Sale |
46.28 |
13,000 |
601,615 |
2,000 |
| AZAB MOHAMMAD | Director |
Dec 19 '23 |
Option Exercise |
9.85 |
4,320 |
42,552 |
74,225 |
| PATOU GARY | Director |
Dec 13 '23 |
Option Exercise |
9.55 |
14,402 |
137,487 |
29,951 |
| PATOU GARY | Director |
Dec 13 '23 |
Sale |
39.29 |
11,380 |
447,085 |
23,573 |
| PATOU GARY | Director |
Dec 13 '23 |
Sale |
41.05 |
7,598 |
311,898 |
4,902 |
0.42%
0.16%
자본화:
|
볼륨(24시간):